Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1 1

Status

Recruiting 2

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Neuroblastoma 8Head and Neck Neoplasms 2Ganglioneuroblastoma 2Central Nervous System Neoplasms 2Brain Neoplasms 2Astrocytoma 2Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Uterine Cervical Diseases 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Oligodendroglioma 1Medulloblastoma 1Lung Neoplasms 1Kidney Neoplasms 1HIV Infections 1Gliosarcoma 1Glioma 1Glioblastoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Cancer Female 1Acquired Immunodeficiency Syndrome 1AIDS-Related Complex 1

Interventions

dinutuximab 3Magnetic Resonance Spectroscopy 3Doxorubicin 3Cyclophosphamide 3Carboplatin 3Biopsy 3Vincristine 2Topotecan 2Thiotepa 2Temozolomide 2Stem Cell Transplantation 2Specimen Handling 2Radiation 2Platinum 2Melphalan 2Isotretinoin 2Irinotecan 2Etoposide 2Cisplatin 21,2-diaminocyclohexaneplatinum II citrate 2sargramostim 1lorlatinib 1etoposide phosphate 1Watchful Waiting 1Transurethral Resection of Bladder 1Razoxane 1Radiotherapy 1Observation 1Nuclear Medicine Department, Hospital 1Leukapheresis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Ganglioneuroblastoma × Isotretinoin × Clear all
NCT06172296 2026-06-03

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 3 Recruiting
478 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

NCT03126916 2026-02-27

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Children's Oncology Group

Phase 3 Recruiting
750 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡